Ib-AMP4 antimicrobial peptide as a treatment for skin and systematic infection of methicillin-resistant Staphylococcus aureus (MRSA)

Samira Sadelaji 1, Ehsanollah Ghaznavi-Rad 1, 2, Shabnam Sadoogh Abbasian 1, Shohreh Fahimirad 1, Hamid Abtahi 1*

1 Molecular and Medical Research Center, Arak University of Medical Sciences, Arak, Iran
2 Department of Medical Laboratory Sciences, Arak School of Paramedicine, Arak University of Medical Sciences, Arak, Iran

A R T I C L E  I N F O
Article type: Original
Article history:
Received: Oct 17, 2021
Accepted: Feb 1, 2022

Keywords:
Antimicrobial activity
Recombinant Ib-AMP4
Skin and systematic - infection
Staphylococcus aureus

A B S T R A C T
Antimicrobial peptide compounds (AMPs) play important roles in the immune system. They also exhibit significant anti-tumor and antibacterial properties. Most AMPs are cationic and are able to bind bacterial cell membranes through electrostatic affinity. Ib-AMP4 is a plant-derived AMP that exerts rapid bactericidal functions. In the present study, the antibacterial efficiency of the produced recombinant Ib-AMP4 in elimination of Methicillin-resistant Staphylococcus aureus (MRSA) bacterial infection, was investigated under in vitro and in vivo situations.

Materials and Methods: The synthesized Escherichia coli codon-optimized gene sequences of the Ib-AMP4 were expressed in E. coli BL21 (DE3) pLysS. The recombinant Ib-AMP4 was purified and refolding conditions were optimized. The antibacterial efficiency of the refolded peptide against MRSA was tested under in vitro and in vivo situations for treatment of skin and systematic infection of MRSA in a mouse model.

Results: Antibacterial assays confirmed the antibacterial function of Ib-AMP4 against MRSA. SEM results proved the destructive effects of applying Ib-AMP4 on MRSA biomembrane. Time-kill curve and growth kinetic assay illustrated rapid antibacterial activity of the produced Ib-AMP4. Moreover, Ib-AMP4 showed significant infection treatment ability in a mouse model and all infected mice receiving Ib-AMP4 protein survived and there was no trace of bacteria in their blood samples.

Conclusion: The results confirmed the rapid antibacterial potential of the produced recombinant Ib-AMP4 to be used for efficient treatment of MRSA infection.

Introduction
Antibiotic resistance is considered one of the major public health challenges. By the way, most conventional antibiotics are rendered ineffective by drug-resistant pathogenic bacteria. This phenomenon as a growing global crisis has turned into a serious human health threat (1). Therefore, research for finding alternative antibacterial drugs has been increased in recent years. Antimicrobial peptides (AMPs) are small proteins able to kill various microorganisms. The antibacterial properties of AMPs are due to their ability to disrupt cell biomembranes by electrostatic attachment to bacterial cell wall, whereas conventional antibiotics destroy cell walls by binding to specific targets. This different mechanism of function rarely causes AMPs resistance observation among bacterial cells (2, 3).

Ib-AMP4 is a plant defense antimicrobial peptide with a net charge of +6, derived from impatients balsamina seeds. Cysteine residues at positions 6, 7, 16, and 20 of the Ib-AMP4 sequence (QWGRRCCGWPGPRYCRYWCC) make two intermolecular disulfide bonds in the arrangement Cys6–Cys16 and Cys7–Cys20 that increase its stability in the liquid substrate. The highly cationic Ib-AMP4 peptide were investigated for significant bactericidal properties against both Gram-positive and Gram-negative bacteria (4). Solid-phase chemical synthesis leading to small amounts of peptides have been produced via solid-phase chemical synthesis. Whereas, methods based on biotechnological techniques are capable of generating higher quantities of peptides efficiently. Using a bacterial host for recombinant production of AMPs has resulted in production of considerable amounts of peptides (5).

This study describes application of the recombinant fusion protein Ib-AMP4 in the treatment of infection caused by MRSA in vivo. Ib-AMP4 was studied for the activities against fungi and bacteria in vitro. Besides, it was also applied for bacterial discrimination in previous reports. Ib-AMP4 has never been applied in vivo to assess its ability against pathogens. This is the first report of in vivo study of Ib-AMP4.

Materials and Methods
Materials and chemicals
Ampicillin, Chloramphenicol, Nutrient agar, Nutrient broth, and Mueller Hinton media (MHA, MHB) were
purchased from Merck (Germany), and resazurin sodium salt of BDH (INGLAD) and Ni-NTA kit from Qiagen (USA). All other chemicals used were of analytical grade.

**Bacterial strains**

The antibacterial activities of this peptide were assessed against *Staphylococcus aureus* (MRSA) (ATCC 25923). *E. coli DH5α* was used as the cloning host. *E. coli BL21 (DE3)* pLYS was employed as the recombinant protein expression host, and pET32a was applied as the recombinative expressive vector.

**Construction of the expression vector pET32a-IbAMP4**

The entire gene sequence, which comprises 5’ BamHI, an Ib-AMP4 (UniProt: 024006), and Xho I 3’ was designed and codon-optimized for *E. coli* expression. The whole construct was synthesized by Biomatik Company (Cambridge, ON, Canada) and inserted into the plasmid pET32a (Novogene) as the expression vector. The pET32a-IbAMP4 construct was transferred into competent *E. coli DH5α* bacteria. PCR and mini-preparation plasmid were applied to confirm bacterial colonies that carried recombinant constructs (6).

**Production of recombinant Ib-AMP4**

For expression purposes, competent *E. coli BL21 (DE3)* cells were prepared based on standard protocols and were transformed by the successfully extracted expression vector pET32a-IbAMP4 construct (7, 8). The whole construct was synthesized by Biomatik Company (Cambridge, ON, Canada) and inserted into the plasmid pET32a (Novogene) as the expression vector. The pET32a-IbAMP4 construct was transferred into competent *E. coli DH5α* bacteria. PCR and mini-preparation plasmid were applied to confirm bacterial colonies that carried recombinant constructs (6).

**Purification of Ib-AMP4**

Denaturing conditions using 8 M urea, followed by Ni-NTA agarose resin affinity chromatography were used for purification of the recombinant constructs. Subsequently, SDS-PAGE12% and the absorbance assay at 280 and 260 nm determined FIC values for 2 hr at 37°C. Untreated controls were performed based on CLSI protocol MO7-A10 (12). The MIC test of Ib-AMP4 against MRSA (ATCC 25923) was performed based on CLSI protocol MO7-A10 (12). In advance, a standardized inoculum of bacterial cell suspension 1×10^6 CFU/ml was prepared. Subsequently, 50 µl of MH broth was poured into wells of the 96-well microplates from column 1:10. After that, a two-fold serial dilution of the dialyzed recombinant Ib-AMP4 was made. Column 11, involving 100 µl of bacterial inoculum, was regarded as the positive growth control, and Column12 with 100 µl of the MH was considered as the sterility control. After 24 hr incubation time, 20 µl of resazurin dyes (0.02 %(w/v)) were poured into each well and incubated for another 2 hr at 37°C. The concentration of protein in the final blue color well was recorded as the MIC value. All experiments were repeated triplicate (13).

**Time-kill**

A starting inoculum of 10^5 CFU/ml of tested bacteria in the exponential phase was used for the time-kill assay. Ib-AMP4 with 2×MIC concentrations was employed to assay the peptide effects on cell survival. Samples were collected at 0, 10, 20, 30, 40, 50, and 60 min after incubation and plated on MH agar for colony counting. After subsequent 24 hr of incubation at 37°C, the decline of the viable bacterial cell was determined (14).

**SEM microscopy**

Overnight cultures of the bacterial cell were adjusted to 1×10^6 CFU/ml cell density. Afterward, bacterial cells were treated with IbAMP4 at the determined FIC values for 2 hr at 37°C. Untreated controls were prepared in a BHI medium with the same cell density. The bacterial cells were centrifuged at 12,000×g for 15 min, then washed two or three times and resuspended in sterile PBS. Ten microliters of the tested bacterial suspension were spread onto a microscope slide and fixed in 2.5% glutaraldehyde. Then, samples were coated with gold. The cell morphology was analyzed by SEM (15).

**In vivo Tests**

**Animal model**

All of the *in vivo* experiments were confirmed appropriate by the Ethical Committee of Arak University of Medical Sciences. The Syrian mice were adult males; they weighed about 20–25 grams and were obtained from the Pasteur Institute. Animals were kept in a suitable animal room with 20–25 °C temperature, 50%–70% humidity, and a 12:12 hr light/ dark cycle and were divided into groups of 3. Syrian mice were nourished by specific rodent pellets and urban
Ib-AMP4 as a treatment for skin and systematic infection

Culture of MRSA

The overnight culture of MRSA was grown in fresh BHI and the bacteria were then centrifuged at 10000×g for 10 min, washed, and resuspended in sterile phosphate-buffered saline (PBS). This process was repeated twice, and the bacterial suspension was adjusted to the ultimate density of 1.5×10⁸ colony-forming units CFU/ml.

Topical method

The animals were anesthetized with 50 mg/kg ketamine and 5 mg/kg xylazine. The shaved area of the panniculus carnosus muscle was selected for a 25 mm×20 mm thickness excisional wound. The wound was not sutured or covered. The prepared cell suspension (1.5×10⁸ CFU of MRSA, 10 μl) was equally inoculated on the induced wounds.

Infectious wounds in the Syrian mice

For ensuring the proper infection of wounds, wound sampling was carried out 2 days after the infection, and the samples were cultured on blood agar medium.

Infection treatment

The animals were categorized into three groups of seven mice, randomly. Group 1 was treated with mupirocin 2% ointment (positive control), group 2 was treated topically with the simple ointment prepared from recombinant protein Ib-AMP4 (4×MIC) and group 3 did not receive any treatment (negative control). Each Syrian mouse was secured in a cage and fed individually and kept under controlled environmental conditions. The Syrian mice were anesthetized by ketamine and then a 2×2 cm region of the posterior part of the neck was shaved for skin injury.

Wound infection was performed by MRSA (1.5×10⁸ CFU/ml). Treatment of the skin infections followed 1 hr after wound colonization. Treatment continued for 7 days, once every 12 hr. During the wound healing period, the wound areas were measured.

The percentage of wound healing was calculated as follows:

\[
\text{Wound healing percentage} = \left(\frac{A_0 - A_{\text{scar}}}{A_0}\right) \times 100 \%
\]

Where A₀ and Aascar are original wound and scared areas, respectively.

Systemic infection

Intrapertoneal (IP)

In the systematic method, MRSA bacteria were injected the intraperitoneally (IP). 1 ml of bacteria was injected IP into each Syrian mouse with 2×10⁸ CFU/ml concentration. Then, the produced peptide (1 ml with 4×MIC concentrations) was injected IP 2 times with an interval of 12 hr for 48 hr (16).

The Syrian mice were divided into six groups of five.

Group 1: Drug control (positive control) (vancomycin): 200 μg / ml

Group 2: Control group (negative control) (mice infected with MRSA bacteria)

Group 3: Recombinant protein treatment group with a concentration of 200 μg/ ml

Group 4: Recombinant protein treatment group with a dose of 100 μg/ ml

Group 5: Recombinant protein treatment group with a dose of 50 μg/ ml

Group 6: Recombinant protein treatment group with a dose of 25 μg/ ml

Supplementary tests

Control Group

After the death of the Syrian mice in the control group, blood samples were collected to confirm the bacteria. 5 ml of blood from rat heart was added to BHI sterile liquid culture medium and then incubated overnight at 37 °C. To confirm bacteria, a pure plate method and differential culture medium were used to identify MRSA.

Protein-receiving groups

72 hr following the first protein injection, one Syrian mouse from each group was killed as a sample. Afterward, about 5 ml of blood was collected from the heart of each sample and added to a sterile BHI culture medium. It was then incubated for 18 hr. Subsequently, 10 μl of the above culture medium was cultured in a blood agar medium for confirmatory tests.

Extraction and culture of spleen

Seventy-two hr after the first protein injection, one Syrian mouse from each group was killed as a sample. Their spleens were then extracted and washed with PBS buffer. Under sterile conditions and using a laminar hood, we perfused the spleen. Ultimately, about 100 μl of the contents inside the spleen were cultured on agar.

Results

Expression of Ib-AMP4 in Escherichia coli BL21 (DE3) pLYsS

Protein production in various tested induction conditions was analyzed with SDS-PAGE. The greatest yield was achieved by applying 1.5×NB and 0.5 mM IPTG. Overnight incubation of induced medium under 200 rpm shaking at 37 °C was the most convenient condition. The produced 22 kDa protein after 24 hr and 2 hr of the induction is indicated with corresponding arrows in Figure 1.

Purification of Ib-AMP4

SDS-PAGE was used to analyze the quality of purified protein by nickel nitrilotriacetic acid-agarose (Figure 2).

Refolding of Ib-AMP4

The results of the dialysis in phosphate-buffered saline
(PBS) buffers at different pHs revealed that pH 7 was the most effective for proper protein refolding. Ib-AMP4 concentration after the dialysis procedure was about 100 µg/ml which was not sufficient for further assays. The problem was solved by utilizing amplicon centrifuging filters, yielding proteins with 400 µg/ml concentration.

**In vitro tests**

**Determination of MIC**

The MIC value of Ib-AMP4 against MRSA is presented in Figure 6. The MIC value of recombinant Ib-AMP4 against MRSA was recorded at 1.5 μg/ml. As shown in Figure 6, the highest concentration of protein was poured into the first well of a 96 well plate. Then the protein concentration was serially diluted by half (well numbers 1-10). Positive control was MHB (well number 12) and negative control was a culture of MRSA (well number 11). Resazurin was used for visualization of the MIC results. The blue color indicates a decrease in the number or absence of viable bacteria. While the red color represents the growth of the bacteria (Figure 3).

**Time-kill**

Time-kill test was employed to investigate of time-dependent impacts of recombinant IbAMP4 exposure on bacterial cell viability. The result of time-kill confirmed complete cell death occurred within 50 min (Figure 4).

**SEM microscopy**

The SEM results illustrated the cell wall destruction induced by recombinant IbAMP4 on MRSA cells. This phenomenon led to cell wall deformation and consequently end to cell component leakage. These defects cause cell death.

**In vivo tests**

**Topical method**

Figure 6 illustrates a representative Syrian mice wound healing model from each group (control, recombinant Ib-AMP4, and mupirocin) on days four and seven after treatment. The results confirmed that treatment with recombinant Ib-AMP4 caused a faster wound closure in Syrian mice when compared with other groups.

Moreover, assessment of wound healing percentage at defined days indicated the most increased healing percentage was recorded for group B in comparison with other groups (group A= 60 %, group B= 96%, group C= 80% ) (Figure 7).

**Systematic method**

**Infection of Syrian mice**

The IP method was used to administer MRSA to infect Syrian mice.
Negative and positive control groups

The results of the present study revealed that all Syrian mice in the negative control group died 12 hr after bacterial injection. Also, the results of Syrian mice in the positive control group showed that 60% of Syrian mice receiving the drug died within 24–48 hr. The presence of MRSA in blood samples taken from dead Syrian mice was confirmed. Moreover, MRSA was just detected in bacteria taken from dead Syrian mice. Therefore, infection with MRSA had occurred as expected (Figure 8).

Protein group

The recombinant Ib-AMP4 protein was injected into the Syrian mice (IP). The injectable doses of protein were 200 μg / ml, 100 μg / ml, 50 μg / ml, and 25 μg / ml. Moreover, the protein injection time was immediately after the bacterial injection. The number of injections was four times with an interval of 12 hr. The findings of this study show that all Syrian mice receiving all the proteins survived. Also, no symptoms of bacteria were detected in the blood and spleen samples of Syrian mice in the peptides used groups (Figure 9).

Discussion

The growing development of drug-resistant pathogens has enhanced the risks of antibiotic-resistant microbe spread as a serious worldwide health crisis. In order to create more efficient methods for prevention of infections, the search for alternative antibiotics has turned into a worldwide health priority (17).

Due to cationic properties, AMPs are able to bind bacterial cell walls with a negative charge. Moreover due to amphiphilic properties of AMPs, they induce holes or make destructive effects on bacterial cell membranes that can lead to cell lysis and consequently cell death (18).

Methicillin-resistant *Staphylococcus aureus* (MRSA) infection is caused by a specific strain of *S. aureus* that is resistant to some antibiotics including methicillin. MRSA is considered a major cause of hospital- and community-acquired infections. Thus, providing alternative treatment for MRSA infection has been placed at the center of researchers’ attention (19).

In the present study, the antibacterial function of the recombinant Ib-AMP4 peptide against MRSA infection...
has been evaluated. It has been proven that Ib-AMP4 peptide indicates a broad range of antibacterial properties and suppresses the growth of both gram-positive and gram-negative bacteria efficiently (20). In this report, the Ib-AMP4 corresponding gene sequence was successfully expressed in E. coli. The recombinant protein with high purity was obtained through nickel affinity chromatography. The results of antimicrobial activity assays confirmed that the refolding process in a neutral buffer (pH=7) led to the most active form of the peptide. The refolded recombinant Ib-AMP4 exhibited significant antimicrobial function against MRSA (ATCC 25923). Considerable antibacterial properties of Ib-AMP4 were proven by previous research (21, 22). It has been shown that the antibacterial function of Ib-AMP4 is due to its ability to attach to bacterial cell membranes and expand cell lysis by creating disorders through cell membrane integrity (23). Time-kill results indicated a sharp reduction of MRSA cell viability within the first 50 min of exposure to the refolded recombinant Ib-AMP4. In addition, in vivo studies of Ib-AMP4 potential in the healing of MRSA infected wounds, confirmed the higher efficiency of Ib-AMP4 in comparison with mupirocin ointment.

Plus, the healing efficiency of Ib-AMP4 in systematic infection was confirmed under in vivo situations by treatment of systematic MRSA-infected Syrian mice. While MRSA-infected Syrian mice died within 12–24 hr after being injected with the bacterium, all of the infected mice treated with the recombinant Ib-AMP4 survived. Noticeably, the blood samples taken from the mice treated with the produced recombinant protein did not show any traces of MRSA bacteria in the blood agar medium. While the culture of the blood samples taken from the control Syrian mice illustrated extended growth of bacteria.

Overall, all performed antimicrobial tests demonstrated significant antimicrobial activities of the recombinant Ib-AMP4. Thus, the recombinant Ib-AMP4 peptide can be considered a reliable alternative candidate for treatment of patients with infections caused by S. aureus after subsequent needed clinical trials steps.

**Conclusion**

Antimicrobial assessments consistently revealed the notable efficiency of the produced recombinant Ib-AMP4 against MRSA bacteria under in vitro and in vivo situations.

**Acknowledgment**

This research was supported by financial assistance from the Molecular and Medicine Research Center of Arak University of Medical Sciences, Arak, Iran. The authors would like to thank the Deputy of Research and Technology of Arak University of Medical Sciences. The results presented in this paper were part of a student thesis.

**Authors’ Contributions**

EGR and HA Designed the experiments; SSA and SS Performed experiments and collected data; EGR and HA Discussed the results and strategy; EGR, SF, and HA Supervised, directed, and managed the study; SSA and HA Approved the final version to be published.

**Conflicts of Interest**

The authors declare that no conflict of interest exists.

**References**

18. Nguyen LT, Haney EF, Vogel HJ. The expanding scope of